Background--Intracerebral hemorrhage (ICH) is an acute neurological disorder with high mortality and no effective treatment. In addition to the initial bleeding event, rebleeding and hematoma expansion are associated with poor outcome in these patients. We studied the effectiveness of the new antifibrinolytic agent CM352, a short-half-life matrix metalloproteinase inhibitor, for achieving early hemostasis and improving functional recovery in a rat model of collagenase-induced ICH.
A lthough it comprises only %10% to 20% of all stroke cases, nontraumatic intracerebral hemorrhage (ICH) claims the most lives with 30% to 40% mortality, half of which occurs within 2 days of ICH onset. 1 Hypertension being the most important risk factor, commonly used drugs such as anticoagulants, platelet inhibitors, and thrombolytics (tissue plasminogen activator) increase the risk of ICH. 2, 3 In spite of the tremendous societal and economic burden in the aging population, there is no proven treatment for ICH, and its outcomes and prognosis have not improved significantly. 1 ICH is triggered by vessel rupture and direct blood extravasation in the brain parenchyma, where hematoma mechanically disrupts neighboring blood vessels, increasing bleeding and hematoma growth, leading to ischemia and impaired neuronal function. Consequently, hematoma size and expansion are associated with poor outcome and early neurological deterioration after ICH. 4, 5 Hematoma growth is also followed by a cascade of secondary events: neuroinflammation, edema formation, toxic effects of blood degradation products, leukocyte infiltration and activation, protease release, and further blood-brain barrier disruption, which exacerbate the hemorrhagic lession. 6 Because hematoma expansion is the only modifiable predictor of outcome after ICH, several medical therapies aimed at improving ICH by reducing it have been studied. To date aggressive blood pressure reduction, 7 early neurosurgical intervention, 8 and hemostatic therapy with recombinant active factor VII (rFVIIa) 9 have failed to improve survival or functional outcome after ICH in unselected patients. Because hyperfibrinolysis is an important contributor to major bleeding events and has been associated with ICH, 10 clinical trials are currently being conducted to assess the benefits of antifibrinolytic therapy (tranexamic acid [TXA] ) to reduce hemorrhage and improve ICH outcome. 11 Matrix metalloproteinases (MMPs) have been associated clinically and experimentally with extracellular matrix degradation triggered by inflammation after stroke. Particularly in ICH, MMPs have been proposed to play a main role in bloodbrain barrier disruption, brain edema, and neuronal death. 12, 13 This evidence led to the testing of a variety of broad-spectrum MMP inhibitors in experimental models of ICH. Among them, GM6001 13 and minocycline 14 achieved a significant reduction of secondary brain damage and functional improvement.
We and others have shown that MMPs cooperate with the fibrinolytic system to regulate thrombus dissolution: plasmin is capable of activating specific MMPs, which in turn participate in the dissolution of fibrin through direct targeting or interaction with other components of the fibrinolytic system. 15, 16 A role of MMPs in hemorrhage is also supported by the association between increased levels of certain MMPs and prolonged bleeding in human and animal studies, whereas genetic deletion of MMPs prevented bleeding in experimental models. 17, 18 Furthermore, our research group recently demonstrated that acute and short-term MMP inhibition is an effective and safe therapeutic strategy for the prevention of bleeding. We used GM6001 as a proof of concept and developed CM352, a new short-lived MMP inhibitor and highly efficient antifibrinolytic agent optimized for human blood that does not interfere with normal hemostatic function. 19, 20 Therefore, the aim of this preclinical study was to determine whether CM352 treatment, through dual inhibition of fibrinolysis and proteolysis, can reduce hematoma expansion and improve functional and neurological recovery in a rat model of ICH induced by intraparenchymal injection of collagenase. 
Methods
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Pharmacokinetics Analysis of CM352 in Rat Samples
CM352 solutions were prepared by dissolving the solid in saline. A drug dosage of 1 mg/kg was administered as a single intravenous injection in the femoral vein. Blood was collected into citrated tubes, and plasma was obtained by 2-step centrifugation: first at 600 g for 10 minutes and then at Clinical Perspective What Is New?
• Dual antifibrinolytic and antiproteolytic treatment, with a fastacting short-lived matrix metalloprotease (MMP) inhibitor, can effectively reduce hematoma expansion and brain damage in an experimental model of intracerebral hemorrhage.
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What Are the Clinical Implications?
• Our findings support the use of MMP inhibitors with antifibrinolytic properties for the pharmacological management of intracerebral hemorrhage, a life-threatening condition with no proven treatment.
• This therapeutic approach could be particularly interesting in the setting of hemorrhagic transformation after thrombolytic treatment.
18 000 g for 2 minutes. Plasma samples were stored at À80°C until analysis. CM352 was measured in plasma samples using a Xevo-TQ MS triple quadrupole mass spectrometer with an electrospray ionization source and an Acquity UPLC (Waters, Manchester, UK) as previously reported. 20 Briefly, after chromatographic separation, the compound was detected using multiple reaction monitoring. 
MMP Enzyme Activity Assays
The inhibitory effect of CM352 against MMP-2, MMP-7, MMP-9, and MMP-12 was tested at GenScript (http://www.gensc ript.com/), using GM6001 as reference compound. Protease stock solutions (10 mmol/L) were diluted with assay buffer to make final test solutions containing no more than 2.0% DMSO. The samples were dispensed into plates; substrate was added and read with PHERAstar PLUS (BMG Labtech, Ortenberg, Germany) plate reader.
Collagenase Activity Assay 
ICH Rat Model
The ICH rat model was used as previously described. 
Experimental Groups
Two experimental groups (n=6) were designated: (1) a control group treated with saline (0.9% of NaCl) and (2) a CM352 group treated with 1 mg/kg CM352 in saline. The same experimental design and setting were used to assess the effect of late (3 hours) CM352 treatment. Required sample size was calculated from previous studies using the same model 21 in order to be able to detect a 25% effect size on hematoma growth versus controls (2-tailed t test). Six animals per group are required to detect this difference with a power (1Àb) of 0.8 and a=0.05. N was calculated using EPIDAT software (http://www.sergas.es/Saude-publica/EPIDAT-4-2). All treatments were given as a single bolus (jugular) 60 minutes after the collagenase injection for ICH induction. We have chosen the dose of 1 mg/kg of CM352 because it showed the best pharmacological efficacy in mice in previous in vitro and in vivo studies conducted by our group. 19, 20 Animals without hemorrhage (n=1), with small hemorrhage (n=2), or with hemorrhage located far from the basal ganglia (n=1) were excluded from the study before treatment administration.
The experimental procedure was performed following several criteria derived from the STAIR (Stroke Therapy Academic Industry Roundtable) group guidelines for preclinical evaluation of stroke therapeutics 22 : (1) ICH hematoma was evaluated at 1 hour, before treatment, by T2-weighted magnetic resonance images (MRI) to confirm ICH, as an index of the reliability of the hemorrhagic model; (2) animals were randomly assigned to treatment groups of the study; (3) researchers were blinded to treatment administration; (4) researchers were blinded to treatments during outcome assessment; (5) temperature was controlled during the surgical period; and (6) a pharmacokinetics analysis of CM352 in rat blood samples was also conducted.
Magnetic Resonance Imaging Protocol
Based on a previous hematoma growth profile study, 21 hematoma volumes were assessed basally (1 hour after collagenase injection to induce ICH) and at 3 hours, 24 hours, and 14 days after ICH induction by means of magnetic resonance imaging conducted on a 9.4-T horizontal bore magnet magnetic resonance imaging system (Biospec 94/ 20USR, Bruker BioSpin, Ettlingen, Germany) with 20-cm-wide actively shielded gradient coils (440 mT/m), as previously described. 21 Radiofrequency transmission was achieved with a birdcage volume resonator, and signal was detected using a 4-element surface coil positioned over the head of the animal. Gradient-echo pilot scans were performed at the beginning of each imaging session for accurate positioning of the animal inside the magnet bore. Multislice axial T2-weighted imaging was performed at baseline (1 hour after IHC induction), and at 3 hours, 24 hours, and 14 days after ICH. T2-weighted images were acquired using a RARE (factor n=4) sequence with the following acquisition parameters: Magnetic resonance data analysis was performed using Para Vision (Bruker Medical, Ettlingen, Germany), and images were processed with ImageJ (W. S. Rasband, National Institutes of Health, Bethesda, MD: http://rsb.info.nih.gov/ ij). The analyzed region of interest was the hematoma and lesion region. Hematoma volumes (basal and 3 and 24 hours) as well as lesion volume at day 14 were manually traced from T2 maps, and the mean signal intensity was measured by 2 well-trained imaging analysts blind to the experimental conditions.
Behavioral Tests
Following STAIR criteria, animal models must show neurological and functional deficits in line with the produced lesion. The model of collagenase-induced hemorrhage primarily damages the striatum, producing a small forelimb paresis contralateral to the lesion. Sensorimotor deficits after ischemic insult were assessed using the cylinder test, as previously described. 23 This test evaluates limb asymmetry during the exploratory activity. Each animal was put in a cylinder with a 20-cm-diameter transparent base. A video camera was located under this transparent cylinder for recording the vertical exploratory movements of the animal with its anterior limbs for 2 to 10 minutes, depending on movement grade. For image recording and analysis, VirtulDub software was used. Analyzed behaviors were the numbers of times that the animal touched the cylinder wall and independent use of each limb in contact with the cylinder wall in each upward movement. The laterality index was calculated (the number of times that the animal touched the cylinder with the right leg during the ascendant movement by the number of times that the animals touched with each leg). This index is close to 0.5 for healthy animals and tends to 0 or 1 for animals that have a preferential use of the left or the right paw, respectively. On the other hand, neurological deficit was evaluated with the Bederson scale, 24 ranging from 0 (asymptomatic) to 8 (severe deficit), which included the following items: spontaneous movement, spontaneous rotation, spontaneous flexion of the contralateral forelimb, edge detection, turn after tail suspension, reflection of protection. Behavioral studies were performed at baseline (before surgery) and at 24 hours and 14 days after ICH during the darkness cycle. An experienced investigator, blind to treatment and neuroimaging data, analyzed the behavioral tests.
Blood Samples
Blood samples (0.5 mL) were drawn from the tail vein before surgery, immediately after surgery, and at 1 hour, 3 hours, 24 hours, and 14 days. Citrate or EDTA plasma was obtained by centrifugation, and samples were stored at À80°C. Enzyme-linked immunosorbent assay was used to measure interleukin-6 (IL-6, ref. KRC0061, Life Technologies, Thermo Fisher Scientific, Waltham, MA), cellular fibronectin (ref.
MBS007311, MyBioSource, San Diego, CA), and thrombinantithrombin complex (Enzygnost TAT, ref. OWMG15, Siemens Healthcare, Erlangen, Germany) in plasma, as biomarkers of inflammation, cellular damage, and hypercoagulability, respectively. The intra-assay and interassay coefficients of variation for all molecular markers were <10%.
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were measured with STA-Neoplastin R and PTT reagents (STA-Compact, Stago, Barcelona, Spain). PT results were expressed as percentage of the standard value, and aPTT results were expressed in seconds.
Animal Euthanasia and Brain Cryopreservation
After the completion of the neuroimaging study, 14 days after ICH, animals were euthanized by an overdose of anesthetic (sevoflurane 8%) and perfused with PBS and 4% formaldehyde. The brain was removed, axially sliced (2 mm thick), fixed in 4% formaldehyde (4 hours), transferred to 20% sucrose in PBS (4°C), included in optimal cutting temperature compound (Sakura Finetek, Torrance, CA), and stored at À80°C. Slices
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling and Immunofluorescence
Brain slices were dried at 38°C for 3 hours, and the optimal cutting temperature compound was then removed by washing the slices twice in PBS. Antigen retrieval was performed by immersion of slices in a thermal bath of citrate buffer (pH 6 A quantitative analysis of terminal deoxynucleotidyl transferase dUTP nick end labeling was performed using 3 animals from each group. Photomicrographs were obtained from the perihematoma area. Replicate photomicrographs were obtained from 2 consecutive slices containing the central part of the injured region. Positive nuclei were counted manually.
Statistical Analysis
Results were expressed as meanAEstandard deviation or median [quartiles] for the continuous variables depending on their normal distribution or not, respectively. Statistical analyses were made using Mann-Whitney or Wilcoxon tests when appropriate. A P<0.05 was considered as statistically significant. The statistical analysis was conducted using PASW Statistics 18 for Mac (SPSS Inc, Chicago, IL).
Results
To determine the effect of the novel antifibrinolytic compound CM352 on hematoma growth in a rat model of collagenaseinduced ICH, we used it at the dose (1 mg/kg) previously reported to reduce hemorrhage in mouse tail and liver bleeding models. 20 However, we first performed a detailed in vivo pharmacokinetic study in rats following intravenous administration of 1 mg/kg CM352 in order to validate results previously obtained in mice. 20 As shown in Figure 1 , CM352 reached a maximal plasma concentration of 7.8 lmol/L and showed low plasma protein binding and short half-life (1.09 hours). Low volume of distribution and reduced brain/ plasma ratio indicate that the drug remains mainly in the blood stream. Since CM352 antifibrinolytic efficiency had been previously demonstrated in human and murine blood, 20 we analyzed the effect of CM352 on tissue-type plasminogen activatorinduced fibrinolysis in rat whole blood. As expected, CM352 prolonged clot lysis time in the thromboelastometry assay, delaying fibrinolysis by 50% at a concentration of 3.7 lmol/L in rat blood, higher than the 0.2 lmol/L observed in mouse and 0.7 nmol/L found in man, 20 without changes in coagulation activation and clot firmness. Moreover, we analyzed CM352's effect on MMPs that had been reported to be upregulated after ICH in humans and experimental models.
14, 25 We previously reported that CM352
efficiently inhibited MMP-3 and MMP-10, 20 and in this study we describe that it also inhibits MMP-2, MMP-9, and MMP-12 in the nanomolar range. However, GM6001, the broad-range MMP inhibitor used as reference, was more efficient, particularly in the case of MMP-7 (Table 1) . By contrast, CM352 achieved 50% inhibition of MMP-3 and MMP-10 at a lower dose than GM6001. Because collagenase type VII was used to induce intracerebral hemorrhage, we tested CM352 and observed that it had no significant effect on collagenase activity in the 10 nmol/L to 10 lmol/L range of concentrations (IC50>10 lmol/L). 
CM352 Reduces Hematoma Volume After ICH Induction
As shown in Figure 2A , intraparenchymal injection of collagenase caused an intracerebral hematoma with similar size in all animals at 1 hour, averaging 23.2AE3.5 mm 3 in rats randomized to CM352 and 22.8AE3.1 mm 3 in the control
group. An expected increase in hematoma volume within 24 hours occurred in controls, but, interestingly, magnetic resonance imaging analysis showed a 29% reduction in hematoma volume for CM352-treated rats compared with controls at 3 hours after ICH (P<0.01; Figure 2B ). The difference from controls further increased up to 46% at 24 hours (P<0.01), the time of maximal hematoma volume. Analysis of hematoma expansion showed that CM352 treatment reduced it by 35% at 3 hours (310AE62% versus 200AE86%; P<0.05; Figure 2C ) and by 56% at 24 hours (305AE51% versus 133AE63%; P<0.01; Figure 2C ). Moreover, lesion volume at 14 days in the CM352 group was 48% smaller than that in controls (P<0.01) and even than the basal hematoma volume (P<0.01; Figure 2C ).
CM352 Improves Functional and Neurological Recovery
To determine whether the diminished hematoma expansion observed after CM352 administration could have any effect on the neurological and functional deficits caused by the hemorrhagic lesion, the Bederson scale and laterality test were performed before surgery (baseline) and at 24 hours and 14 days after ICH induction. Sensorimotor deficits were quantified using laterality index, which was close to 0.5 at baseline, before ICH for both experimental groups. Interestingly, as shown in Figure 3A , CM352 induced a better sensorimotor recovery at 24 hours and 14 days compared with the control group (all P<0.01). Moreover, neurological deficit was assessed using the Bederson scale, which was close to 0 at baseline, before ICH for both experimental groups. However, as shown in Figure 3B , CM352 induced a better neurological functional recovery at 24 hours compared with the control group (P<0.01), with this beneficial effect of CM352 also being very noticeable at day 14 (P<0.01).
Reduced Inflammation After ICH
Circulating markers of inflammation (IL-6), blood-brain barrier damage (cellular fibronectin) and hypercoagulability (thrombin-antithrombin complex) were assessed after ICH in order to elucidate whether CM352 treatment could have an impact on these parameters. IL-6 levels increased early after ICH, peaked at 3 hours, and then lowered steadily down to basal values by day 14 ( Figure 3C ). In spite of displaying similar IL-6 concentration at baseline (11.7 [7.6-13.9 ] versus 14.4 [11.4-18.7 ] pg/mL), CM352-treated animals exhibited a significant reduction at 3 hours (P<0.05). By contrast, no differences were found for cellular fibronectin and thrombin-antithrombin complex levels between control and CM352 groups (data not shown).
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling Analysis
A histological analysis performed at 14 days after ICH revealed areas of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive (dead or dying) cells in the perihematomal area in both control and CM352 groups (Figure 4) . No effects on apoptosis in the perihematomal area were observed for CM352 treatment compared to the control group (Figure 4 ).
Late CM352 Administration Reduces Brain Damage After ICH
Late (3 hours) administration of CM352 was tested in the same experimental model of ICH to better define its therapeutic effects. Intraparenchymal injection of collagenase caused an intracerebral hematoma ( Figure 5A) Figure 5B ), and differences in lesion size were patent between the groups up to day 14 (P<0.05). Analysis of hematoma expansion showed that CM352 treatment reduced it by 62% at 5 hours (306AE82% versus 115AE17%; P<0.01; Figure 5C ) and by 58% at 24 hours (274AE69% versus 114AE50%; P<0.01; Figure 5C ). Accordingly ( Figure 5D ), CM352 induced a better sensorimotor recovery at 24 hours and 14 days compared with the control group (all P<0.01). The Bederson scale also showed a better neurological function recovery at 24 hours (P<0.01) and at day 14 (P<0.05; Figure 5E ). PT and aPTT were measured in plasma samples to assess for potential effects of CM352 on extrinsic, intrinsic, or common coagulation pathways. No differences in PT or aPTT were observed between rats treated with CM352 (n=3) and controls (n=3) at any time point (Table 2) .
Discussion
This study reports for first time that a dual antifibrinolytic and antiproteolytic agent (CM352) can effectively reduce hematoma expansion and brain damage in a rat model of collagenase-induced ICH when administered as early (1 hour) or late (3 hours) treatment. These positive effects on hematoma growth are associated with improved neurological and functional recovery.
Main therapeutic interventions after ICH have been directed to either preventing hematoma expansion or protecting the neurovascular unit from secondary brain injury. Strategies addressing hematoma expansion by lowering blood pressure, 7 surgical hematoma removal, 8 reversal of anticoagulants, 3 or hemostatic therapy with rFVIIa 9 have provided evidence of reduced hematoma growth, but results regarding long-term therapeutic benefit have been mainly disappointing. 4 Moreover, to our knowledge, only a few preclinical studies have been conducted to assess the effects of the pharmacological modulation of hematoma growth. 6 On the other hand, MMPs have been implicated in brain injury after ICH in animal models and in humans 12, 13, 26 ; in particular, blood MMP-9 concentration has been associated with hemorrhagic transformation. 27 Rapid MMP upregulation after ICH has been proposed to cause neurovascular matrix degradation, proteolyzing the basal lamina around blood vessels and disrupting endothelial tight junctions, leading to edema, hemorrhage, and cell death. 13 Based on this rationale, early treatment with broad-range MMP inhibitors has been used in experimental models to reduce brain damage after ICH. 13, 14 CM352 is a fast-acting short-lived new antifibrinolytic and broad-range MMP inhibitor that has been demonstrated to be a very efficient antihemorrhagic agent without interfering with normal hemostatic function. 20 We have shown that acute treatment with CM352 after ICH effectively reduces hematoma volume by 55% at 24 hours, which almost doubles the 30% reduction observed for rFVIIa in a similar model. 28 Pharmacokinetic analysis demonstrates that at the therapeutic dose, in spite of its fast clearance rate, CM352 reaches plasma concentration in the micromolar range, as required for fibrinolysis inhibition ex vivo in the thromboelastometric assay with rat whole blood. These results are in accordance with the potent antihemorrhagic activity we had previously demonstrated in murine models of mild and severe bleeding. 20 Moreover, reduction in hematoma expansion achieved with CM352 was accompanied by a substantial improvement in functional and neurological recovery, in marked contrast with clinical trials of rFVIIa, which reduced hematoma growth but did not improve survival or functional outcome after ICH. 9 The use of the antifibrinolytic agents e-aminocaproic acid and TXA has been proposed after ICH (STOP-AUST trial) 11 ; however, the only experimental evidence available shows that TXA exacerbates edema in a mouse model of warfarin-associated ICH. 29 Moreover, in contrast with the potential risk for thrombotic events associated with treatment with rFVIIa, e-aminocaproic acid, or TXA, we have shown that CM352 does not alter hemostasis.
20
CM352 is a dual antifibrinolytic/antiproteolytic agent, and we cannot explain reduced brain damage and improved functional and neurological outcome only through fibrinolysis inhibition. In fact, similar positive results have been obtained after late (3 hours) CM352 administration, when most of the MMPs, which are upregulated after ICH. 14 Moreover, because pharmacokinetic analysis shows that CM352 remains in blood above 10 nmol/L for 8 hours, it could be assumed that it could be actively inhibiting MMPs in this range of time after ICH. On the other hand, increased IL-6 levels had been associated with early hematoma growth in humans, 31 and, accordingly, the reduction in this systemic inflammatory marker observed after CM352 treatment may be the result of the diminished bleeding but also a consequence of MMP inhibition. Interestingly, it had been previously shown, in a collagenase-induced mouse model of ICH, that acute treatment with 100 mg/kg GM6001 (intraperitoneally for 48 hours), but not with 1 mg/kg, reduced leukocyte infiltration, oxidative stress, brain edema, and neuronal degeneration in association with a decrease in lesion volume and improved neurological outcome. 13 This benefit had been explained mainly through preservation of the neurovascular matrix. However, using a mouse model of tail bleeding, we have recently shown that GM6001 at lower dose (1 mg/kg) has antihemorrhagic efficiency comparable to TXA (300 mg/kg), and CM352 is a more potent agent even at much lower doses (0.01 mg/kg). 20 It could also be hypothesized that CM352 is inhibiting other proteases or cell-death pathways involved in brain injury. 6 However, previous off-target selectivity profiling by biochemical characterization against a wide panel of metalloenzymes, including cathepsins, caspases, kalikreins, and neutrophil proteases, showed that CM352 had no significant effect on them. 20 Thus, antihemorrhagic activity leading to reduction of intracerebral bleeding, combined with MMP inhibition, can explain observed benefits of CM352 treatment after ICH. At this point it is noteworthy that antifibrinolytic activity cannot be assumed for all MMP inhibitors but needs to be tested experimentally.
In the normal central nervous system MMPs are expressed at the low levels required for physiological functions. Early (24 hours) broad-range MMP inhibition has been shown to reduce infarct size after focal cerebral ischemia, but delayed MMP inhibition (7 days) was associated with increased infarct volume. 32 In this context intravenous administration and the short half-life of CM352 allow precise administration of the compound and offer an additional benefit by sparing beneficial MMP functions in later stages of tissue remodeling and regeneration after ICH. Finally, we have tested if CM352 could reduce the apoptotic cells in the perihematomal area because it has been suggested that apoptosis represents a prominent form of cell death associated with ICH in the perihematoma region. 33 However, no effects on apoptosis in the perihematomal area were observed for CM352 treatment compared to the control group. This may be because we measured apoptosis at day 14, whereas the maximum apoptosis is described at day 5 after ICH. 33 This study has a number of limitations. It has been designed to assess differences in hematoma volume, the main objective of the study, but it lacks the statistical power required to detect differences in biomarkers of brain or blood-brain barrier damage because of the higher variability found in these parameters. In this model, collagenase injection breaks down small vessels and causes hemorrhage, mimicking spontaneous intraparenchymal bleeding in humans and hematoma expansion that occurs naturally in ICH patients. Moreover, we have used healthy animals, and the effectivity of CM352 should be confirmed in animal models including common ICH comorbidities such as hypertension and anticoagulants. Furthermore, future studies should also be conducted to test this new therapeutic approach in other related clinical settings where bleeding and neurovascular matrix degradation are relevant, such as hemorrhagic transformation of ischemic stroke after thrombolytic treatment or traumatic brain injury, especially in light of recent reports demonstrating the relevance of endogenous fibrinolysis after traumatic brain injury. 10 In conclusion, we have shown that acute short-term treatment with CM352, a dual-acting fibrinolysis and MMP inhibitor, limits brain damage after ICH by reducing hematoma expansion and attenuating early inflammation, leading to improved functional and neurological recovery. These results suggest that CM352 may be an ideal new strategy for treating ICH, warranting clinical trials.
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